Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid Combination in Chronic Hepatitis Related to Metabolic Syndrome Components.
Nae-Yun HeoSeung Ha ParkJoon Hyuk ChoiEunju KimTae Oh KimJongha ParkJin LeeYong Eun ParkEun Hye OhJun Seong HwangSu Jin JeongPublished in: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi (2021)
Biphenyl dimethyl dicarboxylate/ursodeoxycholic acid combination reduced ALT in chronic liver disease related to metabolic syndrome. On the other hand, there is no evidence that this leads to improved hepatic steatosis and fibrosis within 6 months.